Core Viewpoint - A total of 292 listed companies have participated in the establishment of 340 industrial merger and acquisition funds in 2023, with 183 funds completed and 4 halted, indicating a strong trend towards investment in cutting-edge technology and strategic economic sectors to drive innovation and transformation [1] Group 1: Company Initiatives - Nanjing Pharmaceutical Group Co., Ltd. plans to invest 119.8 million yuan, accounting for 59.9% of the total subscription amount, in a new merger and acquisition fund focused on medical devices [1] - The company's "14th Five-Year" strategic plan emphasizes integration into the "Healthy China" initiative, focusing on the health industry and extending the existing industrial chain to explore new spaces for innovation and transformation [2] Group 2: Benefits of Establishing Funds - Establishing industrial merger and acquisition funds allows companies to strategically layout their industrial chains, achieve business synergies, and seize early advantages in innovation [2] - Companies can leverage financial effects by using a small amount of their own funds to attract more social capital, significantly reducing the direct cash flow impact of large-scale mergers [2] - The financial performance can be optimized as costs and risks during the project incubation phase typically do not need to be included in the listed company's financial statements, smoothing out performance fluctuations [2] Group 3: Considerations and Compliance - Companies must ensure strategic alignment with their core business and avoid speculative investments that deviate from their main operations [3] - It is crucial to establish a robust governance structure for the funds to maintain control and prevent conflicts of interest and hasty decision-making [3] - Compliance with information disclosure is essential, including timely updates on fund establishment, investment progress, and related transactions to avoid insider trading and regulatory risks [3]

Core Viewpoint - Nanjing Pharmaceutical Group Co., Ltd. plans to establish a subsidiary investment company focused on the medical device sector, with a significant investment from the company itself, aimed at enhancing its strategic positioning in the industry [1][2]. Group 1: Investment Structure - Nanjing Pharmaceutical will invest approximately 120 million yuan, accounting for 59.9% of the total registered capital of the new investment company [1]. - The investment company will be set up in collaboration with Nanjing New Industry Investment Management Co., Ltd. and Nanjing New Industry Medical Health Strong Chain M&A Equity Investment Fund [1]. Group 2: Target Investment - The newly formed investment company will specifically target an investment in Ningbo Jiangfeng Biological Information Technology Co., Ltd., acquiring approximately 22.5% of its equity, with a total valuation not exceeding 750 million yuan [2]. - Jiangfeng Biological, established in 2011, specializes in digital pathology and is recognized as a national high-tech enterprise focusing on innovative pathology diagnostics [2]. Group 3: Strategic Implications - The investment strategy reflects a model of "core enterprise + state-owned fund + industry chain target," which is expected to accelerate the transformation of technological achievements and promote innovation in the digital pathology field [2]. - This approach serves as a replicable example for local industrial development, encouraging collaboration between core enterprises and state-owned funds to enhance competitiveness and drive industrial upgrades [2].

Group 1 - The company held its fifth meeting of the tenth board of directors on December 18, 2025, with all nine directors present, and all resolutions were passed unanimously [3][6] - The company approved a proposal to invest CNY 119.8 million in establishing the Nanjing New Industry Medical Device Investment Company, which will focus on acquiring a 22.5% stake in Ningbo Jiangfeng Biological Information Technology Co., with a valuation cap of CNY 750 million [4][36] - The board authorized the management to handle all matters related to the investment and establishment of the medical device investment company [4][41] Group 2 - The company decided to change the purpose of repurchased shares from employee stock ownership plans to cancellation and reduction of registered capital, involving 39,852 shares [8][29] - The total share capital will decrease from 1,308,931,240 shares to 1,308,891,388 shares following the cancellation of the repurchased shares [9][34] - This change requires approval from the shareholders' meeting before implementation [29] Group 3 - The company announced that the convertible bonds issued on December 25, 2024, will start paying interest on December 25, 2025, with a coupon rate of 0.20% for the first year [13][21] - The total issuance amount of the convertible bonds is CNY 1,081.49 million, with a face value of CNY 100 per bond [14][15] - The bonds will have a conversion price of CNY 5.29 per share, which has been adjusted to CNY 5.12 [20] Group 4 - The company is participating in the establishment of the Nanjing New Industry Medical Device Investment Company, which is part of a broader strategy to enhance its investment in the healthcare sector [39][40] - The investment aligns with the company's strategic planning to extend its industrial chain and integrate resources in the healthcare industry [39][40] - The company aims to leverage social capital to improve the efficiency of fund utilization through this investment [39][40]

Core Viewpoint - Nanjing Pharmaceutical plans to invest 120 million yuan in a new equity investment company focused on the medical device sector, aiming to acquire a 22.5% stake in Ningbo Jiangfeng Biological Information Technology Co., Ltd, with a total valuation not exceeding 750 million yuan [1][2][3] Group 1: Investment Details - Nanjing Pharmaceutical will contribute 120 million yuan, representing 59.9% of the total capital of the newly established Nanjing New Industry Medical Device Investment Company [1] - The investment will specifically target Jiangfeng Biological, with the acquisition of approximately 22.5% equity based on a valuation cap of 750 million yuan [1][3] Group 2: Strategic Alignment - The investment aligns with Nanjing's municipal strategy to enhance industrial strength and integrate resources within the "2+6+6" innovative industrial system [2] - Nanjing Pharmaceutical's participation in this investment fund reflects its strategic plan to extend its existing industrial chain and embrace the "Health China" development strategy [2] Group 3: Target Company Overview - Jiangfeng Biological has over a decade of experience in the digital pathology industry and is recognized as a national high-tech enterprise focusing on innovative pathology diagnostics [3] - The company operates across five business segments, including digital pathology scanning systems and AI-assisted diagnostic systems, which complement Nanjing Pharmaceutical's digital transformation strategy [3]

Core Viewpoint - Nanjing Medical Pharmaceutical Company plans to invest in a new medical device investment company, indicating a strategic move to enhance its investment portfolio in the healthcare sector [2] Group 1: Investment Details - The company intends to invest 11.98 million RMB, which represents 59.9% of the total subscribed capital of the newly established Nanjing New Industry Medical Device Investment Company [2] - The investment will specifically target Ningbo Jiangfeng Biological Information Technology Co., Ltd., with an overall valuation not exceeding 750 million RMB for the acquisition of approximately 22.5% equity [2] - The final transaction price and key investment terms will be determined by a formal equity investment agreement [2] Group 2: Related Parties and Governance - The investment involves related parties, as Nanjing New Industry Investment Group Co., Ltd., the controlling shareholder of the company, fully owns Nanjing New Industry Investment Management Co., Ltd. [2] - The investment has been approved by the company's board of directors and does not require shareholder meeting approval [2]

（文章来源：证券日报） 证券日报网讯 12月18日晚间，南京医药发布公告称，公司第十届董事会第五次会议审议通过《关于公 司参与设立南京新工南药医疗器械强链并购股权投资有限责任公司暨关联交易的议案》《关于变更回购 股份用途并注销的议案》《关于变更注册资本暨修订〈公司章程〉部分条款的议案》等多项议案。 ...

Group 1 - Zhongwei Company plans to acquire controlling stake in Hangzhou Zhonggui through share issuance, with stock suspension starting December 19, 2025, for up to 10 trading days [1] - Qibin Group's subsidiary plans to establish Shenzhen Qibin New Energy Technology Co., with a registered capital of 600 million yuan to enhance photovoltaic glass supply chain efficiency [2] - Boying Special Welding's HRSG equipment is primarily matched with heavy gas turbines, with a production cycle of about 6 months, responding to increased demand in the U.S. market [3] Group 2 - Hongda Electronics' associate Jiangsu Zhanxin's application for IPO on the ChiNext has been accepted, with Hongda holding 13.79% of shares prior to the offering [5] - Yinxing Energy plans to acquire 50% stake in Tianjing Shenzhou for 20.15275 million yuan, which will enhance its renewable energy capacity [6] - Nandu Power's controlling shareholder has terminated plans for a change in control, leading to stock resumption on December 19, 2025 [7] Group 3 - Xibu Mining's subsidiary has obtained a mining license for iron resources, supporting sustainable development in the iron resource sector [9] - Shandong Expressway plans to provision for a long-term equity investment impairment of approximately 690 million yuan related to Dongxing Securities [10] - Tianfeng Securities has signed a supplementary agreement to extend the term of a 4 billion yuan subordinated debt by one year, with an adjusted interest rate of 4% [11] Group 4 - Shandong Zhanggu has received an administrative regulatory decision from the Shandong Securities Regulatory Commission for various compliance issues [12] - Nanjing Pharmaceutical plans to invest 120 million yuan to establish a medical device investment company, focusing on acquiring a stake in Ningbo Jiangfeng [13] - Hailianxun has received approval from the CSRC for a share swap merger with Hangzhou Steam Turbine, proceeding with related transactions [14] Group 5 - Luyuan Pharmaceutical reports normal operations with no significant changes in the internal and external business environment [15] - Nanhua Futures has set the H-share public offering price at 12 HKD per share, with expected listing on December 22, 2025 [17] - Visionox plans to invest 3.918 billion yuan in the second phase of the Hefei Guoxian AMOLED production line project, increasing its stake to 37.73% [18] Group 6 - Sichuan Road and Bridge has been acquired by Zhong Postal Insurance, reaching a 5% stake [19] - Boshuo Technology's directors plan to reduce their holdings by up to 18,300 shares [20] - O-film's controlling shareholder transferred 67.7048 million shares to settle debts, maintaining control with a 5.78% stake post-transfer [21] Group 7 - Junshi Biosciences' shareholder plans to reduce holdings by up to 2% through block trading [22] - Lihu Co. plans to reduce holdings by up to 2.98% through various trading methods [23] - Ruichen Environmental plans to reduce holdings by up to 3% through trading [25] Group 8 - Zhongfutong received a winning bid notification for a project worth approximately 411 million yuan [29] - Shikong Technology won a 141 million yuan project for smart cultural tourism integration [30] - Ningbo Construction's subsidiary won a 747 million yuan engineering project [31]

南京医药表示，江丰生物基于完整的研发、生产和销售体系，在数字病理领域打造的全产业链与公司跨 地区、广泛的业务网络和完善的供应链体系具有良好的协同互补效应，亦符合公司数字化转型战略发展 方向。通过公司多维度赋能，预计能够促进江丰生物产品价值转化，拓宽收入边界，实现价值提升。 北京商报讯（记者 丁宁）12月18日晚间，南京医药（600713）发布公告称，公司拟与南京新工新兴产 业投资管理有限公司、南京新工医疗健康强链并购股权投资基金合伙企业（有限合伙）共同投资设立南 京新工南药医疗器械强链并购股权投资有限责任公司（暂定名，以公司登记机关核准名称为准，以下简 称"南药医疗器械投资公司"），其中公司拟出资1.2亿元，占南药医疗器械投资公司认缴出资总额的 59.9%。 公告显示，南药医疗器械投资公司成立后，专项用于投资宁波江丰生物信息技术有限公司（以下简 称"江丰生物"）。南药医疗器械投资公司将以江丰生物整体估值不超过7.5亿元为前提受让江丰生物约 22.5%的股权。 ...

Core Viewpoint - Nanjing Pharmaceutical plans to invest 120 million yuan in a new investment company focused on the medical device sector, specifically targeting a stake in Ningbo Jiangfeng Biological Information Technology Co., Ltd. [1][2] Group 1: Investment Details - Nanjing Pharmaceutical will hold a 59.9% stake in the newly established Nanjing XG South Medicine Medical Device Investment Company, which will focus on acquiring approximately 22.5% of Jiangfeng Biological at a valuation not exceeding 750 million yuan [1][2] - The investment aligns with Nanjing's municipal strategy to enhance industrial strength and integrate resources within the "2+6+6" innovative industrial system [2] Group 2: Strategic Alignment - The establishment of the investment fund is part of Nanjing Pharmaceutical's "14th Five-Year" strategic plan, which emphasizes the integration of health industry development and digital transformation [2] - The investment is expected to enhance the company's core competitiveness while extending its existing industrial chain [2] Group 3: Target Company Overview - Jiangfeng Biological has over a decade of experience in the digital pathology sector and is recognized as a national high-tech enterprise [3] - The company offers a comprehensive range of products and services, including digital pathology scanning systems and AI-assisted diagnostic systems, positioning it as a leader in the industry [3] - Jiangfeng's strong R&D capabilities and established market presence are expected to complement Nanjing Pharmaceutical's extensive business network and supply chain [3]

关于变更注册资本暨修订《公司章程》部分条款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：600713 | 证券简称：南京医药 | 编号：ls2025-165 | | --- | --- | --- | | 债券代码：110098 | 债券简称：南药转债 | | 南京医药集团股份有限公司 1 2025 年 12 月 18 日，南京医药集团股份有限公司（以下简称"公司"）第 十届董事会第五次会议审议通过《关于变更回购股份用途并注销的议案》《关于 变更注册资本暨修订<公司章程>部分条款的议案》，根据《上市公司股份回购 规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等法律法规 及《公司章程》的有关规定，公司拟对 2025 年回购股份 3.9852 万股的回购用途 由"用于员工持股计划或股权激励"变更为"用于注销并减少注册资本"，即拟 对回购专用证券账户中剩余的 3.9852 万股进行注销并相应减少公司注册资本。 本次回购注销完成后，公司总股本将由 1,308,931,240 股（2025 年 ...